EOLS News and Press, Evolus Inc. From 05/10/24

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that its Chief Financial Officer, Sandra Beaver, has been awarded Outstanding CFO of a Public Company by the Orange County Business Journal. The awar...

2024-05-07 23:27:09 ET Evolus, Inc. (EOLS) Q3 2024 Earnings Conference Call May 7, 2024 04:30 PM ET Company Participants Nareg Sagherian - VP and Head, Global IR and Corporate Communications David Moatazedi - President and CEO Rui Avelar - CMO and Head, Research ...

2024-05-07 16:16:23 ET More on Evolus Evolus: Smooth Progress As Management Targets $700m Aesthetics Franchise Revenues By 2028 Evolus, Inc. 2023 Q4 - Results - Earnings Call Presentation Evolus, Inc. (EOLS) Q4 2023 Earnings Call Transcript Evolus Q1 2024 Ear...

Q1 2024 Net Revenue of $59.3 Million, Up 42% from Q1 2023 Non-GAAP Loss from Operations of $0.9 Million, on Track to Non-GAAP Profitability 1 in Q4 2024 and Full Year 2025 U.S. Clinical Trials Completed for Evolysse ® Lift and Smooth fillers, FDA Submission Expect...

Aterian Inc. (ATER) is expected to report for Q1 2024 Dorman Products Inc. (DORM) is expected to report $0.82 for Q1 2024 Hillman Solutions Corp. (HLMN) is expected to report $0.08 for Q1 2024 Wake Forest Bancshares, Inc. (WAKE) is expected to report for quarter end 2024-03-31 Inn...

2024-04-30 22:14:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its first quarter 2024 financial results on Tuesday, May 7, 2024, after the U.S. financial markets close. Evolus management will ...

The article published in Aesthetic Surgery Journal supports safety and duration of effect for temporary improvement in the appearance of moderate to severe glabellar lines presented at the 2023 ASDS Annual Meeting Data showed duration effect of 26 weeks, or 6 months, based on a ≥ 1...

2024-04-16 10:47:43 ET More on AbbVie AbbVie: Great To Be Proven Wrong - Still Not A Buy AbbVie: Bulletproof Fundamentals AbbVie: Despite The Run, Shares Still Look Attractive, Yielding 3.67% AbbVie keeps Humira market share near 100% despite biosimilars: rep...

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced that members of its management team will present at the following investor conference in April: Event: The 23 rd Annual Needham Virtual Healthcare Conference Date...